Saumitra Sengupta

USPTO Granted Patents = 12 (Patent Applications = 2)

CIPO Patents = 2 (Patent Applications = 2)

EPO Patents = 5 (Patent Applications = 3)

Average Co-Inventor Count = 5.4

ph-index = 3

Forward Citations = 65(Granted Patents)

Location History:

Basel, CH (2012)
Kolkata, IN (2013 - 2021)

Company Filing History:

Asana Biosciences, LLC

Aurigene Discovery Technologies Limited

where one patent can have more than one assignee

Years Active: 2012-2021

Loading Chart...

12 patents (USPTO):Sort by Forward Citations

Abstract keywords

1. 10912779 - Quinazolines and azaquinazolines as dual inhibitors of RAS/RAF/MEK/ERK and PI3K/AKT/PTEN/mTOR pathways (2021-02-09),

2. 10226468 - Quinazolines and azaquinazolines as dual inhibitors of RAS/RAF/MEK/ERK and PI3K/AKT/PTEN/mTOR pathways (2019-03-12),

3. 9757382 - Quinazolines and azaquinazolines as dual inhibitors of RAS/RAF/MEK/ERK and PI3K/AKT/PTEN/mTOR pathways (2017-09-12),

4. 9499495 - Quinazolines and azaquinazolines as dual inhibitors of RAS/RAF/MEK/ERK and PI3K/AKT/PTEN/mTOR pathways (2016-11-22),

5. 9339501 - 17a-hydroxylase/C17,20-lyase inhibitors (2016-05-17),

6. 9029399 - [object Object] (2015-05-12),

7. 8962637 - Bicyclic compounds and their uses as dual c-SRC/JAK inhibitors (2015-02-24),

8. 8946260 - [object Object] (2015-02-03),

9. RE45173 - Inhibitors of CYP 17 (2014-09-29),

10. 8575161 - Benzofurane, benzothiophene, benzothiazol derivatives as FXR modulators (2013-11-05),

11. 8440679 - Bicyclic compounds and their uses as dual c-SRC / JAK inhibitors (2013-05-14),

12. 8263635 - Inhibitors of CYP 17 (2012-09-11),

Title: Saumitra Sengupta: Innovator in Pharmaceutical Chemistry

Introduction

Saumitra Sengupta is a prominent inventor based in Kolkata, India. He has made significant contributions to the field of pharmaceutical chemistry, particularly in the development of novel compounds for therapeutic applications. With a total of 12 patents to his name, his work focuses on addressing critical health challenges.

Latest Patents

One of Saumitra Sengupta's latest patents involves the creation of quinazolines and azaquinazolines as dual inhibitors of the RAS/RAF/MEK/ERK and PI3K/AKT/PTEN/mTOR pathways. This patent outlines the synthesis of these compounds and their pharmaceutically acceptable salts. The compounds are designed to co-regulate the aforementioned pathways by administering a therapeutically effective amount to patients. These innovative compounds are particularly useful in treating conditions associated with the dysregulation of these pathways, including various forms of cancer characterized by abnormal cellular proliferation.

Career Highlights

Throughout his career, Saumitra Sengupta has worked with notable companies such as Novartis AG and Asana Biosciences, LLC. His experience in these organizations has allowed him to refine his expertise in drug development and innovation.

Collaborations

Saumitra has collaborated with esteemed colleagues, including Mark G. Bock and Christoph Gaul. These partnerships have contributed to the advancement of his research and the successful development of his patented compounds.

Conclusion

Saumitra Sengupta's contributions to pharmaceutical chemistry and his innovative patents highlight his role as a key figure in the fight against diseases like cancer. His work continues to pave the way for new therapeutic solutions.

This text is generated by artificial intelligence and may not be accurate.